Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00839319 · ClinicalTrials.gov registry record · Phase 1
HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone
A Phase 1 study of Healthy Males, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT00839319 is a Phase 1 study of Healthy Males that has completed, run by University of Washington. The registered enrollment target is 59 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00839319, a Phase 1 study of Healthy Males, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this investigational study is to determine how much male hormone, testosterone, is necessary to maintain sperm production in the testis. This knowledge will be used to help in the development of a safe male hormonal contraception.
Conditions Studied
Interventions
- DRUG Acyline
- OTHER placebo hCG (no active ingredient)
- DRUG hCG (human chorionic gonadotropin)
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00839319
The ClinicalTrials.gov registry entry for NCT00839319 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Males appearing as the primary indexed condition, and to 3 interventions - of which Acyline is the first listed.
NCT00839319 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00839319 about?
NCT00839319 is a clinical study titled "HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone". The purpose of this investigational study is to determine how much male hormone, testosterone, is necessary to maintain sperm production in the testis. This knowledge will be used to help in the development of a safe male hormonal contraception.
What is the current status of trial NCT00839319?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2009-03. Estimated completion is 2010-11.
What conditions does trial NCT00839319 study?
This clinical trial studies the following conditions: Healthy Males.
What interventions are being tested in trial NCT00839319?
The interventions under investigation include: Acyline (DRUG), placebo hCG (no active ingredient) (OTHER), hCG (human chorionic gonadotropin) (DRUG).
Who is sponsoring clinical trial NCT00839319?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00839319 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Males
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.